PLX3397, a CSF-1R inhibitor, promotes the polarization of TAMs from an M2 phenotype to an M1 phenotype, delaying tumor growth and improving survival in hepatoma models [165]. This evidence concerns the gene CSF1R and hepatocellular carcinoma.